- Home
- ALX vs RCUS Comparison
ALX vs RCUS Comparison
Compare ALX & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALX
- RCUS
- Stock Information
- Founded
- ALX 1928
- RCUS 2015
- Country
- ALX United States
- RCUS United States
- Employees
- ALX N/A
- RCUS N/A
- Industry
- ALX Real Estate Investment Trusts
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- ALX Real Estate
- RCUS Health Care
- Exchange
- ALX Nasdaq
- RCUS Nasdaq
- Market Cap
- ALX 1.2B
- RCUS 1.4B
- IPO Year
- ALX N/A
- RCUS 2018
- Fundamental
- Price
- ALX $217.72
- RCUS $15.72
- Analyst Decision
- ALX Sell
- RCUS Buy
- Analyst Count
- ALX 1
- RCUS 12
- Target Price
- ALX $125.00
- RCUS $34.50
- AVG Volume (30 Days)
- ALX 10.8K
- RCUS 932.9K
- Earning Date
- ALX 11-04-2024
- RCUS 11-06-2024
- Dividend Yield
- ALX 8.29%
- RCUS N/A
- EPS Growth
- ALX N/A
- RCUS N/A
- EPS
- ALX 9.25
- RCUS N/A
- Revenue
- ALX $233,399,000.00
- RCUS $263,000,000.00
- Revenue This Year
- ALX N/A
- RCUS $112.97
- Revenue Next Year
- ALX N/A
- RCUS N/A
- P/E Ratio
- ALX $23.48
- RCUS N/A
- Revenue Growth
- ALX 8.52
- RCUS 119.17
- 52 Week Low
- ALX $182.59
- RCUS $13.50
- 52 Week High
- ALX $251.63
- RCUS $20.31
- Technical
- Relative Strength Index (RSI)
- ALX 35.60
- RCUS 43.78
- Support Level
- ALX $215.27
- RCUS $15.03
- Resistance Level
- ALX $233.77
- RCUS $18.98
- Average True Range (ATR)
- ALX 7.10
- RCUS 1.02
- MACD
- ALX -0.96
- RCUS -0.04
- Stochastic Oscillator
- ALX 9.08
- RCUS 20.07
About ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing and redeveloping its properties. It has six properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.